MO129COMPARATIVE EFFECTIVENESS OF SGLT2I VERSUS DPP4I ON CARDIOVASCULAR AND RENAL OUTCOMES IN ROUTINE-CARE SETTINGS
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab092.007
Abstract: While clinical trials have demonstrated the efficacy of SGLT2 inhibitors on preventing cardiovascular and renal damage, few studies have expanded this evidence to routine-care settings. We compared clinical outcomes of adults who started SGLT2i or… read more here.
Keywords: sglt2i; routine care; dpp4i; cardiovascular renal ... See more keywords
Comparison of effectiveness and drug cost between dipeptidyl peptidase‐4 inhibitor and biguanide as the first‐line anti‐hyperglycaemic medication among Japanese working generation with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Evaluation in Clinical Practice"
DOI: 10.1111/jep.13171
Abstract: Abstract Aims and Objectives Dipeptidyl peptidase‐4 inhibitor (DPP4i) is widely used for the treatment of type 2 diabetes (T2DM) in several countries such as Japan, whereas biguanide (BG; mostly metformin) is recommended as a first‐line… read more here.
Keywords: first line; dpp4i; medication; dipeptidyl peptidase ... See more keywords
Identification of distinct epitopes in dipeptidyl peptidase-4 inhibitor–associated bullous pemphigoid
Sign Up to like & getrecommendations! Published in 2025 at "Science Advances"
DOI: 10.1126/sciadv.adv9423
Abstract: Bullous pemphigoid (BP) is a common autoimmune skin disorder caused by autoantibodies targeting BP180. Recent evidence shows that dipeptidyl peptidase-4 inhibitors (DPP4i), used in diabetes management, can induce BP (DPP4i-BP). DPP4i-BP differs from typical BP… read more here.
Keywords: identification distinct; dpp4i; bullous pemphigoid; dipeptidyl peptidase ... See more keywords
Abstract P281: Pre-Stroke Use of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients May Reduce Neurological Severity at the Onset of Stroke: A Retrospective Cohort Study
Sign Up to like & getrecommendations! Published in 2024 at "Circulation"
DOI: 10.1161/circ.149.suppl_1.p281
Abstract: Introduction: Functional outcomes after acute stroke (AS) are related to the initial neurological severity. Therefore, neuroprotective agents to reduce initial brain damage at AS onset shows promise as a preventive approach. Dipeptidyl peptidase 4 inhibitors… read more here.
Keywords: use; pre stroke; dpp4i; neurological severity ... See more keywords
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
Sign Up to like & getrecommendations! Published in 2017 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-017-0640-5
Abstract: BackgroundWhether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of… read more here.
Keywords: associated lower; dpp4i users; lower risk; study ... See more keywords
In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
Sign Up to like & getrecommendations! Published in 2021 at "Endocrine journal"
DOI: 10.1507/endocrj.ej20-0620
Abstract: In this study, we compared the efficacy of a dipeptidyl peptidase-4 inhibitor (DPP4i) to improve glucose control in patients with type 2 diabetes mellitus (T2DM) with or without Hashimoto's thyroiditis (HT). First, we compared the… read more here.
Keywords: peptidase inhibitor; patients type; dpp4i; dipeptidyl peptidase ... See more keywords
750-P: Association of Glucagon-Like Peptide 1 Receptor Agonists with Incident Parkinson’s Disease in U.S. Older Adults with Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2024 at "Diabetes"
DOI: 10.2337/db24-750-p
Abstract: Background: Previous studies suggested the possibility of disease-modifying effects for glucagon-like peptide-1 receptor agonists (GLP-1RAs), but the evidence on the association between GLP-1RAs and risk of Parkinson’s disease(PD) remains to be clarified. Methods: This population-based… read more here.
Keywords: disease; none; glp 1ra; use ... See more keywords
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2021.747620
Abstract: Introduction: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 diabetes mellitus remain unknown. This study aimed to evaluate the effects of the two… read more here.
Keywords: sodium glucose; dementia; study; dpp4i ... See more keywords
Primary Occurrence of Cardiovascular Events After Adding Sodium–Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
Sign Up to like & getrecommendations! Published in 2023 at "Annals of Internal Medicine"
DOI: 10.7326/m22-2751
Abstract: BACKGROUND The effectiveness of glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in preventing major adverse cardiac events (MACE) is uncertain for those without preexisting cardiovascular disease. OBJECTIVE To test the hypothesis that… read more here.
Keywords: receptor agonists; dpp4i; peptide receptor; glucagon like ... See more keywords